Dario investors - sep 26

LabStyle Innovations Corp. (DRIO: OTCBB)End to End Smart Solutions for Diabetics in a Mobile Age

Corporate Presentation - September 27, 2013 Aegis Healthcare Conference Las VegasDr. Oren Fuerst, Executive Chairman & Erez Raphael, President/CEO

Dario

נגטיב� לוגו

Saturday, September 28, 13

Disclaimer Regarding Forward-Looking Statements This presentation of LabStyle Innovations Corp. (the “Company”) and statements of the Company’s management or agents related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions all denote forward-looking statements within the meaning of the Act. Factors that could cause or contribute to such differences include the Company’s compliance with regulatory requirements, the Company’s status as a new public company, the impact of current and any future competition, as well as other factors and risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. In addition, readers are cautioned that any estimates, forecasts or projections contained in this presentation or as may be discussed by Company management or its agents have been prepared by Company management in good faith on a basis believed to be reasonable. However, such estimates, forecasts and projections involve significant elements of subjective judgment and analysis and no representation can be made as to their attainability. No representation or warranty (express or implied) is made or is to be relied upon as a promise or representation as to the future performance of the Company. Readers are cautioned that such estimates, forecasts or projections have not been audited and have not been prepared in conformance with generally accepted accounting principles.



Delaware Company Founded 2011, based on IP from 2010

Share Price $2.79. Market Cap $55MShares Outstanding 19.284M (Float ~ 11.5M shares)Public Since March 2013 (Through S1)Raised $16M, including $10M in May 2013

Developer of Dario, an all-in-one mobile and cloud based diabetes management system with glucose measurement device, data capture and analytics, sharing and social features enabling proactive care





LabStyle Innovations (DRIO:OTCBB) Corporate Snapshot




2013 2022

$12b

$27b(Up 170%)400m

diabetics

20-30%insulin dependent

80-120mPrimary initial target users

Global glucose self-monitoring market (primarily test strips)

Large and Growing Global Marketנגטיב� לוגו


2011 2018

$37b

$72b

2011 2030

10% CAGR

370m

550m

Source: Transparency Market Research, "Global Diabetes Devices Market and Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share and Forecast, 2011 - 2018,"

Global Diabetes (therapeutics devices and drugs) market

Number of Diabetics Worldwide

Diabetes: A Large and Growing Market נגטיב� לוגו


Creating the ‘Artificial Diabetes Brain’, as a springboard of services and products leading to healthier and better life of diabetics worldwide.

DarioValue Proposition






Strips


Insulin




Strips


Diabetes Complications

Insulin




Strips


Diabetes Complications

Insulin




Strips


Dario: “Artificial Diabetes Brain”, All-in-one mobile and cloud based diabetes management system with glucose measurement device, data capture and analytics, sharing and social features

-Concluded usability and accuracy studies -Obtained CE Mark for Europe. UK, Belgium, Italy distribution agreements- Software launch on European Appstore Q4- 510(k) path for the USA

-Reimbursable, recurring, test strips revenue based model-Expanding into a hub of solutions for Diabetics (e.g. revenue from integration with smart insulin pens; clinical studies; product market testing)

-More than 400M diabetics worldwide (close to 100M are insulin dependent). -$12bn test strips market and growing ($37bn overall diabetes market) -Very little real innovation






LabStyle InnovationsInvestment Theme


Enter Dariowww.mydario.com


Enter Dariowww.mydario.com




Social Network - Crowd Source

Multi Mobile Platform - Cloud Service

Monitoring Dario Software

Easy to use, Stylish, All in

One Monitoring

Device

Actionable Personalized

Insights

Improve Diabetic Health - Monitoring to Therapy

Dario End to End Lifecycleנגטיב� לוגו

Therapy

Insulin (Pens; pumps),

Diabetic Food,Exercise,Behavior


1990s 2000s

Glucose Self-Monitoring DevicesHave changed much over the past years



http://chocolateonmycranium.blogspot.com/2011/05/changes.html#.T8Yc05kthbo

Device

Lancer

Strips

A bulky Kit Cumbersome to Carry





Data is Lostנגטיב� לוגו


Smartphone-driven Glucose Meter

Lancing device and strip container

Patent-pending technology

DarioThe Device

Pocket Size Glucose Meter

Stylish and easy to use



Community Based - Learn and Share

Data Analysis and Insights

Proactive Recommendation Based on Pattern Recognition

End To End Diabetes Lifestyle Management (Food, Exercise, Insulin Intake)





Comprehensive Platform - Patient, Care Giver, Professional Healthcare


DarioThe Software


Goals and Objectives via Gamificationנגטיב� לוגו


DarioThe App



Physician Dietitian

NurseOthercare

givers

PatientREAL-TIME DATA

HISTORICAL DATA

TAILOR-MADE DATAANALYZED DATA

Dramatically improving information flow among patients and care givers


Phone + meter Meter + lancer

Current AttemptsCombine Hardware - Rather than providing an E2E Customer Experience



Combining direct to consumers and distributors model

Test strips are typically fully reimbursed; Alignment with HC Insurance Agenda

Data enables a natural expansion into insulin delivery (e.g. smart insulin pen)

Initially: Recurring, high margin revenue from sales of strips





Platform enables revenue from clinical studies and data (e.g. pharma; food)

User base enables product partnerships (e.g. pharma; food)



Revenue ModelHighlights



Illustration: 5 Strips/day*$0.5/Strip*365days/year*100,000 clients>$90M/year








Oren Fuerst, PhDExecutive Chairman

Erez RaphaelCEO & President

Tal GivolyCTO

Seasoned medtech entrepreneur and investorFormer faculty Yale and Columbia Business SchoolExtensive experience in medical devices and data mgt

Former Chief Scientist of Amdocs (NYSE:DOX)More than 25 years in software developmentSoftware inventor with more 25+ granted patents

Prof. Itamar Raz MDHead of SAB

Head of Diabetes Unit and Research Center, Hadassah Medical Center ; Israel National Council of Diabetes of the Israel Ministry of Health; President, Israel Diabetes Research Group.

20 years of experience in product design, development and commercialization. Formerly with Amdocs (NYSE: DOX) and Nokia-Siemens

Shosh FriedmanVP Clinical and Regulatory

Affairs

Former SVP Clinical and Regulatory Affairs at Given Imaging (NASDAQ:GIVN). More than 20 years in clinical, regulatory affairs and QA systems.


Experienced Management Team


Oren Fuerst, PhDCo-Founder

Malcolm Hoenlein

Prof. Nahum Melumad PhD

Adam Stern

Seasoned entrepreneur and investorFounder of Tevel Global & Strategic Models Former faculty Columbia Business School. Extensive experience in medical devices and data management

CEO, Executive Vice-Chairman, Conference of Major American Jewish OrganizationsDirector, Council of Foreign Relations

Professor of Accounting and Business Law, Columbia Business SchoolConsultant to J&J, Bristol-Myers, GE

Head of Private Equity Banking at Aegis Capital and CEO of SternAegis Ventures Director inVivo, Organovo, Prolor20+ years of investment experience

David Weintraub MDCo-Founder

Co-founder, Medical Director Ramat-Aviv MCSerial entrepreneur and inventorFounder of Versamed (acquired by GE)

Itamar Raz MDHead of Diabetes Unit, Hadassah Medical CenterHead, Israel National Council of DiabetesPresident, Israel Diabetes Research Group


Board of directors


Dario: “Artificial Diabetes Brain”, All-in-one mobile and cloud based diabetes management system with glucose measurement device, data capture and analytics, sharing and social features

-Concluded usability and accuracy studies -Obtained CE Mark for Europe. UK, Belgium, Italy distribution agreements- Software launch on European Appstore Q4- 510(k) path for the USA

-Reimbursable, recurring, test strips revenue based model-Expanding into a hub of solutions for Diabetics (e.g. revenue from integration with smart insulin pens; clinical studies; product market testing)

-More than 400M diabetics worldwide (close to 100M are insulin dependent). -$12bn test strips market and growing ($37bn overall diabetes market) -Very little real innovation






LabStyle InnovationsInvestment Theme


Dario

Thank You!




Physician Dietitian

NurseOthercare

givers

Patient

Big Data and Proactive Care at its best

REAL-TIME DATAHISTORICAL DATA

TAILOR-MADE DATAANALYZED DATA

•Pattern Recognition to yield personalization of Insulin Regimen

•New regimen tested in real time

•Real-Time clinical and marketing studies potential (Recruitment; Data capture; Analysis)

•Prediction of Diabetes complications and the need for immediate actions


Health & Medicine

Dario investors - sep 26